2026· International review of neurobiology· Vol 191, pp.
403-446
· 0 citations
Medicine
TL;DR
This chapter examines the clinical utility of key blood-based biomarkers, including phosphorylated tau, amyloid-β ratios, neurofilament light chain, and glial fibrillary acidic protein, within the context of current diagnostic frameworks.
This chapter highlights a overview of blood-based biomarkers emerging in the field of AD and PD, exploring the clinical utility of core pathology markers (Aβ42/40, p-tau species, and α-synuclein), alongside other neurodegenerative markers such as neurofilament light chain and glial activation markers like GFAP.
Priya, Radhika Mittal, Jyotirmoy Banerjee et al.· International review of neur...· 0 citations
The blood-based biomarkers represent a transformative step toward early diagnosis, large-scale screening, and precision medicine in AD, with significant potential for the development of disease-modifying therapies.
Greata Rubavathi Eliazer, Mahesh Kandasamy· International review of neur...· 0 citations
BACKGROUND
Implementation of disease-modifying anti-amyloid therapies for Alzheimer's disease remains constrained by the cost and procedural burden of positron emission tomography and cerebrospinal fluid testing. This review evaluates blood-based biomarkers in therapeutic pathways.
METHODS
PubMed/MEDLINE and Embase w...
This chapter explores the pathophysiology of Alzheimer's Disease to identify peripheral molecular markers associated with these early events and facilitate the development of combinatorial therapies.
Sakshi Kumari, Amaan Rais, Mohd Suhail Ashar et al.· International review of neur...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.